Topical Compositions For Treating Skin Ailments

An over-the-counter cream or ointment composition for topically treating skin disorders including acne, folliculitis, rosacea and boil, said cream or ointment composition comprising:

• a first active ingredient selected from the antibiotic group consisting of:
• bacitracin ointment containing, in each gram, 500 units of bacitracin;
• bacitracin zinc ointment containing, in each gram, 500 units of bacitracin zinc;
• chlortetracycline hydrochloride ointment containing, in each gram, 30 milligrams of chlortetracycline hydrochloride;
• neomycin sulfate ointment containing, in each gram, 3.5 milligrams of neomycin;
• neomycin sulfate cream containing, in each gram, 3.5 milligrams of neomycin;
• tetracycline hydrochloride ointment containing, in each gram, 30 milligrams of tetracycline hydrochloride;
• combination of bacitracin-neomycin sulfate ointment containing per gram 500 units of bacitracin and 3.5 milligrams of neomycin;
• combination of bacitracin-neomycin sulfate-polymyxin B sulfate ointment containing per gram—in a suitable ointment base—(i) 500 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• combination of bacitracin-polymyxin B sulfate topical aerosol containing per gram 500 units of bacitracin and 5,000 units of polymyxin B;
• combination of bacitracin zinc-neomycin sulfate ointment containing per gram 500 units of bacitracin and 3.5 milligrams of neomycin;
• combination of bacitracin zinc-neomycin sulfate-polymyxin B sulfate ointment containing per gram:
• (i) 400 units of bacitracin, 3 milligrams of neomycin, and 8,000 units of polymyxin B;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• or (iii) 500 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• or (iv) 500 units of bacitracin, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B;
• combination of bacitracin zinc-polymyxin B sulfate ointment containing, in each gram, 500 units of bacitracin and 10,000 units of polymyxin B;
• combination of bacitracin zinc-polymyxin B sulfate topical aerosol containing, in each gram, 120 units of bacitracin and 2,350 units of polymyxin B;
• combination of bacitracin zinc-polymyxin B sulfate topical powder containing, in each gram, 500 units of bacitracin and 10,000 units of polymyxin B;
• combination of neomycin sulfate-polymyxin B sulfate ointment containing, in each gram, 3.5 milligrams of neomycin and 5,000 units of polymyxin B:
• combination of neomycin sulfate-polymyxin B sulfate cream containing, in each gram, 3.5 milligrams of neomycin and 10,000 units of polymyxin B;
• combination of oxytetracycline hydrochloride-polymyxin B sulfate ointment containing, in each gram, 30 milligrams of oxytetracycline and 10,000 units of polymyxin B;
• or
• combination of oxytetracycline hydrochloride-polymyxin B sulfate topical powder containing, in each gram, 30 milligrams of oxytetracycline and 10,000 units of polymyxin B with a suitable filler;
• a second active ingredient selected from the combination of first aid antibiotic active ingredients and local anesthetic active ingredients group consisting of:
• bacitracin ointment containing, in each gram, 500 units of bacitracin and any single amine or “caine”-type local anesthetic ingredient;
• bacitracin-neomycin sulfate-polymyxin B sulfate ointment containing, in each gram, in a suitable ointment base the following:
• (i) 500 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• bacitracin-polymyxin B sulfate topical aerosol containing per gram 500 units of bacitracin and 5,000 units of polymyxin B and any single amine or “caine”-type local anesthetic active ingredient;
• bacitracin zinc-neomycin sulfate-polymyxin B sulfate ointment containing per gram:
• (i) 400 units of bacitracin, 3 milligrams of neomycin, 8,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (iii) 500 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (iv) 500 units of bacitracin, 3.5 milligrams of neomycin, 10,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• bacitracin zinc-polymyxin B sulfate ointment containing per gram 500 units of bacitracin, 10,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or
• neomycin sulfate-polymyxin B sulfate cream containing per gram 3.5 milligrams of neomycin, 10,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• a third active ingredient selected from the vasoconstrictor group consisting of:
• phenylephrine HCl preferably 0.25% by weight with acceptable range of 0.125% to 1.0% by weight;
• ephedrine sulfate 0.1 to 1.25 percent;
• epinephrine 0.005 to 0.01 percent;
• epinephrine hydrochloride 0.005 to 0.01 percent;
• phenylephrine hydrochloride 0.25 percent;
• phenylephrine hydrochloride 0.125% to 1.0% by weight;
• ephedrine sulfate 0.1 to 1.25 percent by weight;
• epinephrine 0.005 to 0.01 percent by weight;
• epinephrine hydrochloride 0.005 to 0.01 percent by weight;
• or
• phenylephrine hydrochloride 0.25 percent by weight;
• a fourth active antifungal ingredient selected from the antifungal group consisting of:
• clioquinol 3 percent;
• haloprogin 1 percent;
• miconazole nitrate 2 percent;
• pramoxine hydrochloride 1 percent;
• tetracaine 0.5 to 1 percent;
• povidone-iodine 10 percent;
• tolnaftate 1 percent;
• clotrimazole 1 percent;
• and
• a plurality of seventh inactive excipient ingredients selected from the excipient group consisting of cocoa butter;
• glycerin;
• mineral oil;
• liquid petrolatum;
• white petrolatum;
• cottonseed oil;
• sodium pyruvate;
• tocopheryl acetate;
• eucalyptus oil;
• purified water;
• and sorbitan, wherein each admixture of said first active ingredient, said second active ingredient, said third active ingredient, said fourth active ingredient are blended with sufficient inactive excipient ingredients to from said cream or said ointment composition.

An over-the-counter cream or ointment composition for topically treating skin disorders including acne, folliculitis, rosacea and boil, said cream or ointment composition comprising:

• a first active ingredient selected from the antibiotic group consisting of:
• bacitracin ointment containing, in each gram, 500 units of bacitracin;
• bacitracin zinc ointment containing, in each gram, 500 units of bacitracin zinc;
• chlortetracycline hydrochloride ointment containing, in each gram, 30 milligrams of chlortetracycline hydrochloride;
• neomycin sulfate ointment containing, in each gram, 3.5 milligrams of neomycin;
• neomycin sulfate cream containing, in each gram, 3.5 milligrams of neomycin;
• tetracycline hydrochloride ointment containing, in each gram, 30 milligrams of tetracycline hydrochloride;
• combination of bacitracin-neomycin sulfate ointment containing per gram 500 units of bacitracin and 3.5 milligrams of neomycin;
• combination of bacitracin-neomycin sulfate-polymyxin B sulfate ointment containing per gram—in a suitable ointment base—(i) 500 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• combination of bacitracin-polymyxin B sulfate topical aerosol containing per gram 500 units of bacitracin and 5,000 units of polymyxin B;
• combination of bacitracin zinc-neomycin sulfate ointment containing per gram 500 units of bacitracin and 3.5 milligrams of neomycin;
• combination of bacitracin zinc-neomycin sulfate-polymyxin B sulfate ointment containing per gram:
• (i) 400 units of bacitracin, 3 milligrams of neomycin, and 8,000 units of polymyxin B;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• or (iii) 500 units of bacitracin, 3.5 milligrams of neomycin, and 5,000 units of polymyxin B;
• or (iv) 500 units of bacitracin, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B;
• combination of bacitracin zinc-polymyxin B sulfate ointment containing, in each gram, 500 units of bacitracin and 10,000 units of polymyxin B;
• combination of bacitracin zinc-polymyxin B sulfate topical aerosol containing, in each gram, 120 units of bacitracin and 2,350 units of polymyxin B;
• combination of bacitracin zinc-polymyxin B sulfate topical powder containing, in each gram, 500 units of bacitracin and 10,000 units of polymyxin B;
• combination of neomycin sulfate-polymyxin B sulfate ointment containing, in each gram, 3.5 milligrams of neomycin and 5,000 units of polymyxin B:
• combination of neomycin sulfate-polymyxin B sulfate cream containing, in each gram, 3.5 milligrams of neomycin and 10,000 units of polymyxin B;
• combination of oxytetracycline hydrochloride-polymyxin B sulfate ointment containing, in each gram, 30 milligrams of oxytetracycline and 10,000 units of polymyxin B;
• or
• combination of oxytetracycline hydrochloride-polymyxin B sulfate topical powder containing, in each gram, 30 milligrams of oxytetracycline and 10,000 units of polymyxin B with a suitable filler;
• a second active ingredient selected from the combination of first aid antibiotic active ingredients and local anesthetic active ingredients group consisting of:
• bacitracin ointment containing, in each gram, 500 units of bacitracin and any single amine or “caine”-type local anesthetic ingredient;
• bacitracin-neomycin sulfate-polymyxin B sulfate ointment containing, in each gram, in a suitable ointment base the following:
• (i) 500 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• bacitracin-polymyxin B sulfate topical aerosol containing per gram 500 units of bacitracin and 5,000 units of polymyxin B and any single amine or “caine”-type local anesthetic active ingredient;
• bacitracin zinc-neomycin sulfate-polymyxin B sulfate ointment containing per gram:
• (i) 400 units of bacitracin, 3 milligrams of neomycin, 8,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (ii) 400 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (iii) 500 units of bacitracin, 3.5 milligrams of neomycin, 5,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or (iv) 500 units of bacitracin, 3.5 milligrams of neomycin, 10,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• bacitracin zinc-polymyxin B sulfate ointment containing per gram 500 units of bacitracin, 10,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient;
• or
• neomycin sulfate-polymyxin B sulfate cream containing per gram 3.5 milligrams of neomycin, 10,000 units of polymyxin B, and any single amine or “caine”-type local anesthetic active ingredient.
• a third active ingredient selected from the vasoconstrictor group consisting of:
• phenylephrine HCl preferably 0.25% by weight with acceptable range of 0.125% to 1.0% by weight;
• ephedrine sulfate 0.1 to 1.25 percent;
• epinephrine 0.005 to 0.01 percent;
• epinephrine hydrochloride 0.005 to 0.01 percent;
• phenylephrine hydrochloride 0.25 percent;
• phenylephrine hydrochloride 0.125% to 1.0% by weight;
• ephedrine sulfate 0.1 to 1.25 percent by weight;
• epinephrine 0.005 to 0.01 percent by weight;
• epinephrine hydrochloride 0.005 to 0.01 percent by weight;
• or
• phenylephrine hydrochloride 0.25 percent by weight;
• a fourth active antifungal ingredient selected from the antifungal group consisting of:
• clioquinol 3 percent;
• haloprogin 1 percent;
• miconazole nitrate 2 percent;
• pramoxine hydrochloride 1 percent;
• tetracaine 0.5 to 1 percent;
• povidone-iodine 10 percent;
• tolnaftate 1 percent;
• clotrimazole 1 percent;
• a fifth active anesthetic ingredient selected from the anesthetic group consisting of:
• benzocaine 5 to 20 percent;
• benzyl alcohol 1 to 4 percent;
• dibucaine 0.25 to 1 percent;
• dyclonine hydrochloride 0.5 to 1 percent;
• or
• lidocaine 2 to 5 percent;
• a sixth active analgesia ingredients selected from the analgesia group consisting of:
• camphor 0.1 to 3 percent;
• juniper tar 1 to 5 percent;
• or
• menthol 0.1 to 1 percent;
• and
• a plurality of seventh inactive excipient ingredients selected from the excipient group consisting of cocoa butter;
• glycerin;
• mineral oil;
• liquid petrolatum;
• white petrolatum;
• cottonseed oil;
• sodium pyruvate;
• tocopheryl acetate;
• eucalyptus oil;
• purified water;
• and sorbitan, wherein said admixture of each of said first active ingredient, said second active ingredient, said third active ingredient, said fourth active ingredient, said fifth active ingredient and said sixth active ingredient are blended with sufficient inactive excipient ingredients from said plurality of seventh inactive ingredients to form said cream or said ointment composition.